The Latest on Life Science Innovations

The California Biotechnology Foundation is committed to keeping you up to date about the latest breakthroughs in biotech treatments and the impact of one of California’s largest industries in the state and beyond. This newsletter edition, as of June 24, 2026, brings you updates directly from the forefront of medical innovation. Among the notable advancements featured are:

• The FDA expanded approval of Pfizer’s hemophilia drug Hympavzi, allowing it to be used in children ages 6–11 and in patients with certain hard-to-treat forms of hemophilia, giving more patients access to a convenient treatment that helps prevent bleeding episodes.

• Moderna’s experimental mRNA flu vaccine, mFlusiva, received unanimous support from an FDA advisory committee, boosting its chances of becoming the first mRNA-based influenza vaccine approved in the U.S. for adults 50 and older.

• Scientists have identified a 14-protein blood signature that can predict lung cancer risk years before diagnosis and may help target preventive anti-inflammatory treatments to high-risk individuals, potentially opening a new path toward lung cancer prevention.